Risk for squamous-cell carcinoma (SCC) associated with severity of chronic GVHD, duration of therapy, and use of specific drugs (CIBMTR data only)
Risk factors . | Case patients, no. . | Control patients, no. . | RR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Model 1: chronic GVHD grade | |||||
| No chronic GVHD | 11 | 49 | 1.00 | Reference | - |
| Mild | 6 | 30 | 1.03 | 0.32-3.30 | .96 |
| Moderate | 10 | 17 | 2.73 | 0.90-8.35 | .08 |
| Severe | 13 | 6 | 9.93 | 2.79-35.29 | < .001 |
| Model 2: chronic GVHD grade, chronic drug therapy | |||||
| No chronic GVHD, mild grade | 17 | 77 | 1.00 | Reference | - |
| Moderate, AZA | 8 | 6 | 6.32 | 1.71-23.32 | .006 |
| Moderate, other drugs, no AZA | 1 | 11 | 0.28 | 0.03-2.40 | .24 |
| Severe, AZA | 13 | 4 | 16.24 | 4.04-65.34 | < .001 |
| Severe, other drugs, no AZA | 0 | 2 | 0.00 | - | - |
| Unknown drug therapy* | 1 | 2 | - | - | - |
| Model 3: chronic GVHD grade and duration of AZA therapy, mo† | |||||
| Moderate, AZA, 1-11 mo | 2 | 4 | 2.26 | 0.34-15.21 | .40 |
| Moderate, AZA, 12 mo or more | 6 | 2 | 14.96 | 2.08-107.5 | .007 |
| Severe, AZA, 1-11 mo | 1 | 1 | 3.13 | 0.18-54.08 | .43 |
| Severe, AZA, 12-23 mo | 4 | 1 | 16.75 | 1.41-199.0 | .03 |
| Severe, AZA, 24 mo or more | 8 | 2 | 28.84 | 3.06-272.0 | .003 |
Risk factors . | Case patients, no. . | Control patients, no. . | RR . | 95% CI . | P . |
|---|---|---|---|---|---|
| Model 1: chronic GVHD grade | |||||
| No chronic GVHD | 11 | 49 | 1.00 | Reference | - |
| Mild | 6 | 30 | 1.03 | 0.32-3.30 | .96 |
| Moderate | 10 | 17 | 2.73 | 0.90-8.35 | .08 |
| Severe | 13 | 6 | 9.93 | 2.79-35.29 | < .001 |
| Model 2: chronic GVHD grade, chronic drug therapy | |||||
| No chronic GVHD, mild grade | 17 | 77 | 1.00 | Reference | - |
| Moderate, AZA | 8 | 6 | 6.32 | 1.71-23.32 | .006 |
| Moderate, other drugs, no AZA | 1 | 11 | 0.28 | 0.03-2.40 | .24 |
| Severe, AZA | 13 | 4 | 16.24 | 4.04-65.34 | < .001 |
| Severe, other drugs, no AZA | 0 | 2 | 0.00 | - | - |
| Unknown drug therapy* | 1 | 2 | - | - | - |
| Model 3: chronic GVHD grade and duration of AZA therapy, mo† | |||||
| Moderate, AZA, 1-11 mo | 2 | 4 | 2.26 | 0.34-15.21 | .40 |
| Moderate, AZA, 12 mo or more | 6 | 2 | 14.96 | 2.08-107.5 | .007 |
| Severe, AZA, 1-11 mo | 1 | 1 | 3.13 | 0.18-54.08 | .43 |
| Severe, AZA, 12-23 mo | 4 | 1 | 16.75 | 1.41-199.0 | .03 |
| Severe, AZA, 24 mo or more | 8 | 2 | 28.84 | 3.06-272.0 | .003 |
Forty case patients and 102 control patients were included in these analyses.
One case patient and 2 control patients with unknown types of drugs for chronic GVHD were excluded from the analysis
Model 3 reference group consisted of patients with no chronic GVHD or mild grade chronic GVHD (see model 2). Model 3 also accounts for other drug groups and includes variables for moderate, other drugs (no AZA); severe, other drugs (no AZA); and unknown drug therapy